Pint Pharma is a biopharmaceutical company that specialises in the commercialisation of innovative therapies with the potential to transform outcomes in cancer, rare disease and other patient communities across the Latin American region. By collaborating with world-class biotech and pharma companies, Pint Pharma is committed to improving the lives of Latin American patients in areas of significant unmet medical need. The company is headquartered in Europe and counts with over 250 employees across its territories in Latin America including Brazil, Mexico, Argentina, Colombia, Chile, Peru and Ecuador.
Orbitau
Orbitau develops synthetic eye models for surgical training and educational purposes. The models simulate essential steps of cataract surgery and other ophthalmic procedures, allowing residents, fellows, and surgeons to practice surgical maneuvers in a controlled environment, without the use of animal-derived tissues.
NUERNBERGMESSE BRASIL FEIRAS E CONGRESSOS LTDA
NürnbergMesse Brasil is one of the 10 largest event and exhibition organizers in the country. A subsidiary of the NürnbergMesse Group, founded in 1974 in Germany, the company arrived in Brazil in 2009 and quickly established itself in the market. The promoter stands out for the quality of the services and innovations presented at the fairs it organizes. It always brings together a qualified audience, both national and international. Currently, NürnbergMesse Brasil is responsible for the most important business meetings in Latin America, where it brings together suppliers, distributors and resellers from various segments of the economy. The company’s purpose is precisely to help develop the national industry and increase Brazil’s relevance in the foreign market. Therefore, more than presenting solutions, the company promotes experiences, always with the aim of making the participation of exhibitors and visitors unforgettable, in addition to bringing information and knowledge to everyone. Among the main events organized are Expo Revestir, Haus Decor Show, PET South America, PET VET, FCE Pharma, FCE Cosmetique, Analitica Latin America, Glass South America, ABRAFATI SHOW, Catarina Aviation Show and Brazilian Footwear Show.
NINTX – Next Innovative Therapeutics
Nintx sees plant-based natural products as the best platform to develop multi-target therapies against multifactorial diseases as they can modulate targets directly and indirectly via gut microbiome. | Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies with environmental and social impact. To that end, Nintx has established partnerships with research institutes, private companies and investment funds that bring both complementary expertise and financial resources. Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil, targeting multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Nintx owns cutting-edge proprietary technologies, an Agentic AI platform (GAIApath®️) and an artificial gut (xGIbiomics®️), that enable the development of innovative ingredients (pharmaceuticals and nutraceuticals).
MZF4 MEDICAL
Since 1984 we produce a complete range of non-absorbable surgical sutures. More than 400 million meters of polyamide, polypropylene, polyester, silk, and ultra-high molecular weight polyethylene (UHMWPE) sutures are annually exported to over 40 countries. Production capacity, high technical knowledge, robust regulatory system and a huge ready to stock material place MZF4 Medical among the few qualified players supplying the market on a global scale. | Since 1984 we produce a complete range of non-absorbable surgical sutures. More than 400 million meters of polyamide, polypropylene, polyester, silk, and ultra-high molecular weight polyethylene (UHMWPE) sutures are annually exported to over 40 countries. Within the MZF4 20.000m² technological condo a brand-new 5000m² facility started its operations in 2019 to produce 600 million meters of surgical sutures / year, to design and assemble customized implantable textile medical devices for sports medicine market. Production capacity, high technical knowledge, robust regulatory system and a huge ready to stock material place MZF4 Medical among the few qualified players supplying the market on a global scale. | Founded in 1984, MZF4 Medical manufactures a complete range of non-absorbable surgical sutures. Each year, more than 400 million meters of sutures made from polyamide, polypropylene, polyester, silk, and ultra-high molecular weight polyethylene (UHMWPE) are exported to over 40 countries worldwide.Located within MZF4’s 20,000 m² technological complex, a state-of-the-art 5,000 m² facility began operations in 2019. This unit is dedicated to producing up to 600 million meters of surgical sutures per year, as well as the design and assembly of customized implantable textile medical devices for the sports medicine market.Combining high production capacity, strong technical expertise, a robust regulatory system, and extensive ready-to-stock inventory, MZF4 Medical stands among the few globally qualified manufacturers supplying the medical device market at scale.Ana Luiza De Rosa | R&D Manager | +55 11 98635-7561Giorgina Guasti | Sales Manager | +55 11 98251-1833
Multicare Pharma
Your best choice to provide access for patients with rare diseases in Latin America.